Title

Easy as ADC: Antibody Drug Conjugates as a Novel Cancer Therapy

Presenter

Samuel Curtis

Abstract

In recent years, antibody-drug conjugates (ADCs) have become an effective tool for treating various types of cancer. ADCs are complex molecules composed of a monoclonal antibody specific for a tumor-associated antigen, a highly potent, synthetic, cytotoxic agent, and a stable protein linker that connects the cytotoxic agent to the antibody. Upon antibody-antigen recognition on surface of cancer cells, ADCs are internalized by a process known as receptor-mediated endocytosis. Endosomes transport the ADC/antigen complex to lysosomes, in which lysosomal proteolytic enzymes cleave the antibodydrug linker, thereby activating the cytotoxic agent and inducing cell death. By combining the unique targeting of monoclonal antibodies with the potent, cancer-killing ability of cytotoxic drugs, ADCs allow for sensitive discrimination between healthy and cancerous tissue. My research explores ADC design optimization, and the efficacy of ADC treatment across various cancer types.

Faculty Sponsor

Jeff Brown

Sponsor Department/Programs

Biology

Tracks

Cells and Sickness

Location

Science 100

Presentation Type

Oral Presentation

This document is currently not available here.

Share

COinS
 
Apr 11th, 9:45 AM Apr 11th, 10:00 AM

Easy as ADC: Antibody Drug Conjugates as a Novel Cancer Therapy

Science 100

In recent years, antibody-drug conjugates (ADCs) have become an effective tool for treating various types of cancer. ADCs are complex molecules composed of a monoclonal antibody specific for a tumor-associated antigen, a highly potent, synthetic, cytotoxic agent, and a stable protein linker that connects the cytotoxic agent to the antibody. Upon antibody-antigen recognition on surface of cancer cells, ADCs are internalized by a process known as receptor-mediated endocytosis. Endosomes transport the ADC/antigen complex to lysosomes, in which lysosomal proteolytic enzymes cleave the antibodydrug linker, thereby activating the cytotoxic agent and inducing cell death. By combining the unique targeting of monoclonal antibodies with the potent, cancer-killing ability of cytotoxic drugs, ADCs allow for sensitive discrimination between healthy and cancerous tissue. My research explores ADC design optimization, and the efficacy of ADC treatment across various cancer types.